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Abstract
Background: SERPINE2 (serpin peptidase inhibitor, clade E, member 2) has previously been identified as a
positional candidate gene for chronic obstructive pulmonary disease (COPD) and has subsequently been associated
to COPD and emphysema in several populations. We aimed to further examine the role of SERPINE2
polymorphisms in the development of pulmonary emphysema and different emphysema subtypes.
Methods: Four single nucleotide polymorphisms (SNPs) in SERPINE2 were analyzed from 951 clinically and
radiologically examined Finnish construction workers. The genotype and haplotype data was compared to different
emphysematous signs confirmed with high-resolution computed tomography (HRCT), forced vital capacity (FVC),
forced expiratory volume in one second (FEV1), diffusing capacity (DLCO), and specific diffusing capacity (DLCO/VA).
Results: Three of the studied SERPINE2 SNPs (rs729631, rs975278, and rs6748795) were found to be in tight linkage
disequilibrium. Therefore, only one of these SNPs (rs729631) was included in the subsequent analyses, in addition
to the rs840088 SNP which was in moderate linkage with the other three studied SNPs. The rs729631 SNP showed
a significant association with panlobular emphysema (p = 0.003). In further analysis, the variant allele of the
rs729631 SNP was found to pose over two-fold risk (OR 2.22, 95% CI 1.05-4.72) for overall panlobular changes and
over four-fold risk (OR 4.37, 95% CI 1.61-11.86) for pathological panlobular changes. A haplotype consisting of
variant alleles of both rs729631 and rs840088 SNPs was found to pose an almost four-fold risk for overall
panlobular (OR 3.72, 95% CI 1.56-8.90) and subnormal (OR 3.98, 95% CI 1.55-10.20) emphysema.
Conclusions: Our results support the previously found association between SERPINE2 polymorphisms and
pulmonary emphysema. As a novel finding, our study suggests that the SERPINE2 gene may in particular be
involved in the development of panlobular changes, i.e., the same type of changes that are involved in alpha-1-
antitrypsin (AAT) -deficiency.
Background
Pulmonary emphysema is a smoking associated condition
of the lung, which often develops as a component of
chronic obstructive pulmonary disease (COPD). In addi-
tion to emphysema, COPD encompasses chronic bronchi-
tis and small airway disease [1]. Cigarette smoking is the
main environmental risk factor for COPD, but the disease
is also likely influenced by several genes and gene-smoking
interactions.
To date, the only proven genetic risk factor for COPD is
the severe deficiency of alpha-1-antitrypsin (AAT), which
predisposes to early onset panacinar (panlobular) type of
emphysema [2,3]. AAT, a serine protease inhibitor
encoded by the SERPINA1 gene, has a major role in inacti-
vating neutrophil elastase and other proteases thereby
maintaining the protease-antiprotease balance. Distur-
bance of this balance is believed to explain lung destruc-
tion in emphysema [4,5].
Another member of the serpin-family, SERPINE2 (serpin
peptidase inhibitor, clade E [nexin, plasminogen activator
inhibitor type 1] member 2) was identified as a COPD
candidate gene using gene expression analysis of murine
and human lung tissues [6]. In the same study, several sin-
gle nucleotide polymorphisms (SNPs) in SERPINE2 gene
were associated to COPD in family and case-control-based
study populations. Subsequently, the association between
the SERPINE2 SNPs and COPD has been replicated in
two large studies in Caucasian populations (family and
case-control-based) [7] and in one study in a Korean
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population [8]. On the other hand, the association has also
been failed to be replicated in one Caucasian [9] and one
Chinese [10] study.
Since COPD is a heterogenic disease with the inclusion
criteria varying greatly between different studies, the
exact phenotype, to which SERPINE2 gene contributes
to, has remained ambiguous. Recently, however, one
research group has shed light on this issue by examining
the SERPINE2 polymorphisms in relation to computed
tomography (CT) quantified emphysema and airway wall
phenotypes [11]; interestingly, associations were found
between several SERPINE2 polymorphisms and densito-
metric emphysema. In addition, another research group
recently associated SERPINE2 polymorphism with
autopsy diagnosed emphysema among Japanese smokers
[12].
We aimed to verify the potential association between the
SERPINE2 gene variations and radiologically defined
emphysema, and to study further the potential role of
SERPINE2 polymorphisms in the development of airway
limitation and different emphysema subtypes among Fin-
nish Caucasian construction workers. Signs of different
emphysema types (centrilobular, paraceptal, panlobular,
and bullae) were determined from all the study subjects by
using the high-resolution computed tomography (HRCT).
In addition, lung function was examined using spirometry
and diffusing capacity measurements. Based on previous
association studies, four SNPs in the SERPINE2 gene
(rs729631, rs975278, rs6748795, and rs840088) were cho-
sen to be studied in relation to the above factors.
Methods
Study population
This study combines the study populations from two pre-
vious screening studies aiming to detect early occupational
chest diseases among asbestos exposed workers. The first
study group (ASBE, n = 602) was recruited in 1996-1997
and consisted of asbestos exposed subjects who lived in
Helsinki area, were willing to participate, and had asbesto-
sis with or without smoking, or bilateral pleural plaques
without asbestosis and a smoking history for at least 10
years [13,14]. The second study group (ASSE, n = 633)
was recruited in 2003-2004 and consisted of asbestos
exposed subjects from three geographic areas (Helsinki,
Tampere, and Turku), who had participated in the asbes-
tos screening program in 1990-1992 and were heavily
exposed, or who had previously been diagnosed with
asbestos related occupational disease and had visited
wards of occupational medicine in Helsinki and Tampere
for a clinical follow-up [15].
Altogether 178 of the subjects recruited in 2003-2004
had already participated in the first examination in 1996-
1997. They were therefore excluded from the second
patient group in the present study before combining the
data. In the combined study population, blood samples
were available from 1021 subjects, 1013 of whom the
genotyping data was successfully achieved. However, 25
more subjects were excluded because of missing smoking
information and 37 because of insufficient asbestos expo-
sure data. Thus, the final study group consisted of 951
subjects (935 males, 16 females).
An approval for the study was obtained from the local
ethics committee according to the legislation at the time
of the original study. All subjects gave an informed con-
sent to participate in the study.
Radiological examinations
The lungs of the construction workers were imaged prone
in full inspiration with four different scanners: in 1996-
1997 the Picker PO 2000 (Picker International, Cleveland,
USA) device was used, whereas in 2003-2004 Siemens
Somatom Balance (Siemens Medical, Erlangen, Germany)
was used in Helsinki, Siemens Somatom Plus 4 (Siemens
Medical) was used in Tampere, and GE Light-speed 16
Advantage (GE Healthcare, Milwaukee, WI, USA) was
used in Turku.
The HRCT images were printed as hard copies and ana-
lyzed blindly by two (2003-2004) or three (1996-1997)
radiologists. Emphysema was defined as a sharply deli-
neated low-density area according to the criteria and refer-
ence images of Webb et al. [16]. Signs of centrilobular,
paraceptal, panlobular, and bullae-type emphysema was
scored in both lungs by using a scale from 0 to 5: 0 (no
changes), 1 (faint or subnormal abnormalities, in a single
slice or few slices), 2 (slight abnormalities in some slices),
3 (clear abnormalities in several slices), 4 (score between 3
and 5), and 5 (abnormalities widely distributed in the
whole lung, in all or most slices). These emphysema sub-
type scores were added up to form emphysema sum score,
the maximum being 20 [14]. Mean scores of both lungs
were used in the analysis. The intra- and inter-reader con-
sistencies of readings have previously been reported [13].
Lung function examinations
Flow-volume spirometry was performed with a rolling-seal
spirometer (Mijnhard BV, Bunnik, Holland) connected to
a microcomputer (Medikro MR-3; Medikro, Kuopio,
Finland), using the reference values of Viljanen [17] and
the standards of the European Respiratory Society (ERS)
[18]. The following parameters were measured: forced
vital capacity (FVC), forced expiratory volume in 1 second
(FEV1), and the FEV1/FVC ratio.
The single breath diffusing capacity for carbon monox-
ide (DLCO) and specific diffusing capacity (diffusing capa-
city related to alveolar volume DLCO/VA) were measured
by using a Masterlab Transfer or a Compact Lab Transfer
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device (Erich Jaeger, Würzburg, Germany) according to
ERS recommendations [19]. Correction of DLCO was
done according to patient’s actual hemoglobin level.
The lung function variables, excluding FEV1/FVC ratio,
were handled as percent of Viljanen reference values [17]
based on the distribution of values in the reference popu-
lation. The DLCO and DLCO/VA values were considered
decreased if they were < 74% of predicted, the FEV1 and
FVC values were considered decreased if they were < 80%
of predicted, and the FEV1/FVC ratio was considered
decreased if it was < 88% of predicted [17].
Genotyping analyses
DNA was extracted mechanically using Thermo King
Fisher mL (Thermo Fisher Scientific, Erembodegem,
Belgium) from whole blood using Biosprint 15 DNA
Blood Kit (Qiagen, Hilden, Germany) and stored at -20°C
until use.
Three SERPINE2 SNPs (rs729631, rs975278, and
rs6748795) were genotyped using the OpenArray-system
(BioTrove Inc., Woburn, MA, USA), a next-generation
quantitative PCR platform based on TaqMan chemistry.
The assay IDs for TaqMan® SNP Genotyping Assays
spotted on the array were C__803914_10, C__7614671_10,
and C__1677432_10, respectively. Plate format of 16 SNPs
and 144 samples per array was used. The allele calling ana-
lysis was performed using OpenArray™SNP Genotyping
Analysis software (BioTrove Inc., Woburn, MA, USA).
For the fourth analysed SERPINE2 SNP, rs840088, a
TaqMan® SNP Genotyping Assay was purchased from
Applied Biosystems (assay ID: C__7614655_10). The geno-
typing was performed with the Allelic discrimination assay
of the Applied Biosystems 7500 Real-Time PCR system
(Applied Biosystems, Foster City, CA, USA) according to
manufacturer’s recommendations. Sequence Detection
Software 1.4 was used for the allele calling analysis.
For quality control, two independent readers inter-
preted the results and a random selection of 10% of all
samples was re-tested. No discrepancies were discovered
in the replicate tests for rs729631 or rs840088. The
error rate was 1% for rs975278 and 2% for rs6748795.
In addition, to verify the reliability of OpenArray plat-
form, a random selection of 15% of samples were re-
analyzed for rs6748795 SNP with 7500 Real-Time PCR
system using TaqMan® SNP Genotyping Assay (Assay
ID C__7614655_10). No discrepancies were discovered
in the re-analysis.
Statistical analysis
The associations between genotypes/haplotypes, emphy-
sema, and lung function parameters (FEV1, FVC, FEV1/
FVC, DLCO, and DLCO/VA) were evaluated by using linear
regression analysis. Logistic regression analysis was used
to evaluate the potential confounders and to further study
the risk for emphysematous changes and their severity
with certain genotype. Covariates used in the analysis
were: sex, age, pack years (PYs) of smoking, and years of
asbestos exposure for emphysema; sex, age, PYs, years of
asbestos exposure, and height for FEV1/FVC; and PYs and
years of asbestos exposure for FEV1, FVC, DLCO, and
DLCO/VA. Occasionally lacking height data was replaced
by the group mean value (68 replacements).
For stratified analyses on smoking habits the subjects
who had smoked less than 25 PYs were categorised to
mild smokers, and subjects who had smoked for at least
25 PYs were considered moderate/heavy smokers.
All of the data analyses were performed by using the
SPSS version 18.0 (SPSS Inc., Chicago, IL).
The linkage disequilibrium (LD) structure among the
four studied SERPINE2 SNPs was examined using Haplo-
View program, version 4.2 [20]. The SERPINE2 haplotypes
were statistically reconstructed from population genotype
data by using the PHASE program (version 2.1) with the
Markov chain method for haplotype assignments [21].
Our study (n = 951) had 80% power to detect OR from
1.66 to 1.72 depending on the minor allele frequency (21-
28%). After stratifying the subjects according to radiologic
signs, the OR detected with 80% power ranged from 1.82
to 1.90 (subnormal changes, n = 881) and from 2.17 to
2.26 (pathological changes, n = 832). The calculations
were performed by using standard methods and are based
on a two-sided alpha of 0.05.
The c2 analysis was used to test for a deviation from
the Hardy-Weinberg equilibrium (HWE).
Results
The demographics, pulmonary function data and HRCT
characteristics of the construction workers are summarized
in Table 1. All the studied polymorphisms were in HWE.
Figure 1 shows haplotype block structure and pair-wise
LD (D’) values for the studied SERPINE2 SNPs. Three of
the SNPs (rs729631, rs975278, and rs6748795) were found
to be in tight linkage disequilibrium. Therefore, only one
of these SNPs (rs729631) was included in the further sta-
tistical analyses, in addition to the rs840088 SNP which
was in moderate linkage with the other three studied
SNPs.
The rs729631 SNP showed a significant association with
panlobular emphysema (p = 0.003) (Table 2). This associa-
tion was further analysed by dividing the cases according
to the existence of radiologic changes (Table 3). The radi-
ologic signs of emphysema were considered either subnor-
mal if the radiologic score was less than one (less than two
in emphysema sum score), or pathological if the radiologic
score was one or higher (two or higher in emphysema
sum score).
In the stratified analysis, the homozygous variant gen-
otype of rs729631 SNP was found to pose over 2-fold
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risk for panlobular emphysema (OR 2.22, 95% CI 1.05-
4.72) (Table 4). The risk was slightly increased also for
the heterozygotes (OR 1.66, 95% CI 1.15-2.38), and it
appeared to be mainly attributable to the pathological
emphysematous changes; the ORs were 2.19 (95% CI
1.23-3.91) for heterozygous carriers of the variant allele
of rs729631 SNP, and 4.37 (95% CI 1.61-11.86) for
homozygous carriers of the allele. In contrast, the risk
for developing subnormal panlobular emphysema was
not statistically significantly associated with this SNP
(Table 4).
The significant associations were further analysed by
stratifying the study population according to smoking his-
tory. No notable differences were, however, seen between
mild and moderate/heavy smokers in the risk of develop-
ing emphysematous changes of panlobular type associated
with certain SERPINE2 genotypes (data not shown).
The associations between polymorphisms and pul-
monary changes were studied also separately in both
original study populations (see Additional file 1). The
SERPINE2 rs729631 SNP, which was associated with
panlobular emphysema in the whole study population,
showed statistical significance also in both sub-cohorts.
No other significant associations were seen in the sepa-
rate sub-cohorts.
In haplotype analysis of rs729631 and rs840088 SNPs,
four different haplotypes were identified. The most
common of these was GC (wild type-wild type, 55.0%),
followed by GT (24.4%), CC (16.9%), and CT (3.7%).
In a combination analysis, the CC-haplotype (variant
allele for rs729631, wild type allele for rs840088) showed
almost a 1.5-fold risk for overall panlobular emphysema
(OR 1.41, 95% CI 1.04-1.92) and over two-fold risk for
pathological panlobular changes (OR 2.23, 95% CI 1.41-
3.54) in comparison to the most common haplotype with
the wild type allele for both SNPs (GC) (Table 5). The
haplotype with a variant allele for both SNPs (CT) showed
almost a four-fold risk for overall panlobular changes (OR
3.72, 95% CI 1.56-8.90), and subnormal panlobular
changes (OR 3.98, 95% CI 1.55-10.20) in comparison to
the most common haplotype (GC).
We did not find a correlation between the studied SER-
PINE2 SNPs and lung function. However, FEV1 tended to
be lowest in carriers of the homozygous CC variant
rs729631 genotype (GG 77.8%, CG 73.7%, and CC 70.2%
of predicted, respectively) and FVC was significantly lower
(p = 0.011) in carriers of the CC genotype compared to
the GG genotype (94.1%, 85.7% and 81.3% of predicted,
respectively).
Discussion
SERPINE2 has previously been identified as a positional
candidate gene for COPD from a broad linkage region of
chromosome 2q [6]. Since then, several studies have
Table 1 Selected characteristics of the study population
Mean (SD) or N (%) Range
Age, years 63.2 (7.3) 38.4-87.0
Male sex 935 (98.3)
Smoking history
Never smoker 135 (14.2)
Ex-smoker 595 (62.6)
Current smoker 221 (23.3)
Pack years 20.4 (16.7)
Years of asbestos exposure 23.9 (10.7) 0.0-129.0
Emphysema score (n = 352#) 2.00 (2.4)* 0.13-15.0
Centrilobular (n = 228#) 1.23 (1.01)* 0.17-4.0
Paraceptal (n = 170#) 1.00 (0.91)* 0.17-4.7
Panlobular (n = 168#) 0.93 (0.87)* 0.13-4.3
Bullae (n = 125#) 0.70 (0.77)* 0.17-4.17
Lung function, % of predicted
FEV1 (n = 922) 83.4 (18.6) 19.0-138.0
FVC (n = 917) 89.0 (15.9) 33.0-149.0
FEV1/FVC in percentage (n = 915) 93.5 (12.9) 28.3-166.7
DLCO (n = 912) 91.0 (20.2) 22.0-197.0
DLCO/VA (n = 914) 98.3 (18.4) 10.0-157.0
DLCO = Single breath diffusing capacity for carbon monoxide; DLCO/VA = specific diffusing capacity; FEV1 = Forced expiratory volume in 1 second; FVC = forced
vital capacity; SD = standard deviation
N = 951 except as noted
#Number of subjects with emphysema score positive
*The average score of subjects with positive emphysema score
Kukkonen et al. BMC Medical Genetics 2011, 12:157
http://www.biomedcentral.com/1471-2350/12/157
Page 4 of 10
associated SERPINE2 polymorphisms to COPD in differ-
ent populations [6-8].
We examined further the role of SERPINE2 poly-
morphisms in the development of pulmonary disorders,
and report here a significant association between SER-
PINE2 SNPs and panlobular emphysema. These associa-
tions were observed in the whole study population and
independently in both studied sub-cohorts. Two study
groups have recently reported an association between
SERPINE2 and emphysema [11,12], but no previous
study has assessed the role of SERPINE2 polymorphisms
in structurally different emphysema subtypes.
In the current study, the stratified analysis revealed a
two-fold risk for developing panlobular emphysema for
homozygous variant genotypes of SERPINE2 rs729631
SNP. An elevated risk was also observed for the hetero-
zygous carriers of the variant allele of this SNP. More-
over, the risk was as high as four-fold when only
pathological changes were considered. In addition, an
increased risk was detected also for a haplotype com-
posed of the variant alleles of both rs729631 and
rs840088 SNPs.
All SNPs analyzed in this study have previously been
associated to COPD and related phenotypes [6,7,11,12].
However, the findings vary between different studies;
some studies have even reported lack of association
between any of the studied SERPINE2 SNPs and COPD
[9,10].
There are several potential explanations for the contra-
dictory results. One important aspect is the genetic hetero-
geneity; different SERPINE2 SNPs may be involved in
different populations and the pathology of the disease may
also differ between the populations. Another important
issue to consider in this context is the phenotypic hetero-
geneity. In most of the previous studies the COPD patients
have been chosen based on spirometric measurements.
Therefore, the cases in these study populations include
subjects with and without emphysema.
In addition to the current study, two previous studies
have reported association between SERPINE2 genotypes
and emphysema [11,12]. Moreover, the study subjects in
the original study by DeMeo et al. [6] were subsequently
declared to have emphysema [22]. Consequently, the
results from all these three earlier studies [6,11,12] and
the present one actually converge. This suggests that the
disease phenotype behind the observed association
Table 2 Association between SERPINE2 polymorphisms,
emphysema findings and pulmonary function
Phenotype SNP b# p-value
Emphysema score rs729631 0.018 0.570
rs840088 -0.016 0.614
Centrilobular rs729631 0.000 0.987
rs840088 0.008 0.794
Paraceptal rs729631 -0.025 0.440
rs840088 -0.015 0.637
Panlobular rs729631 0.094 0.003*
rs840088 -0.029 0.369
Bullae rs729631 -0.010 0.767
rs840088 -0.028 0.383
FEV1 rs729631 -0.028 0.377
rs840088 -0.002 0.942
FVC rs729631 -0.044 0.182
rs840088 0.025 0.441
FEV1/FVC rs729631 0.004 0.892
rs840088 -0.047 0.124
DLCO rs729631 -0.032 0.310
rs840088 0.014 0.648
DLCO/VA rs729631 -0.011 0.738
rs840088 -0.026 0.401
DLCO = Single breath diffusing capacity for carbon monoxide, % of predicted;
DLCO/VA = specific diffusing capacity, % of predicted; FEV1 = Forced expiratory
volume in 1 second, % of predicted; FVC = forced vital capacity, % of
predicted; #Standardized coefficient b; *p < 0.05. Covariates included in
analysis: Age, sex, PYs, years of asbestos exposure (emphysema and subtypes);
PYs and years of asbestos exposure (FEV1, FVC, DLCO, and DLCO/VA); age, sex,
PYs, years of asbestos exposure, height (FEV1/FVC).
Figure 1 Linkage disequilibrium (LD) between the studied
SERPINE2 polymorphisms among Finnish Caucasian
construction workers. Values of D’ are shown. The haplotype
structure was estimated by using the Haploview program, version 4.2.
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between SERPINE2 and COPD might indeed be struc-
tural emphysema.
The present results indicate that FEV1 and FVC would
be lower in carriers of the SERPINE2 rs729631 CC gen-
otype than in carriers of the GG genotype, whereas no
association was found between the SERPINE2 genotypes
and gas transfer capacity (DLCO or DLCO/VA), which is
usually decreased in emphysema. This may partly be
explained by the examination methodology: HRCT is
very sensitive method and emphysematous changes can
be detected before any drastic decline in lung function
occurs. In addition, in AAT-deficiency, which resembles
the SERPINE2-deficiency, decline in spirometric vari-
ables has been found to be an early phenomenon,
whereas the decline in gas transfer capacity occurs in
later stage of the disease [23]. This may well be also the
case with the SERPINE2, which could explain the lack
of association with gas transfer in the current study.
SERPINE2 belongs to the same serpin-superfamily of
proteins as AAT, a gene deficiency of which is known
to cause emphysema, especially the panlobular type
emphysema. Both SERPINE2 and AAT are known to
inhibit several serine proteases [24-26]. They have not,
however, been demonstrated to share substrate specifi-
city. It has been proposed that SERPINE2 could contri-
bute to the development of COPD through interaction
with matrix metalloproteinases (MMPs) [6]. However,
the exact mechanistic link between panlobular changes
and SERPINE2 remains to be elucidated.
Our study also has some potential limitations. First,
the patients were enrolled in three cities during two
separate primary studies, and therefore four different
HRCT scanners had to be used and as many as seven
different radiologists participated in the image reading.
However, since the Finnish population is very homoge-
nous and the three big cities, where the patients were
enrolled, are all located in the southern Finland near to
each other, we do not believe that geographic origin at
the time of the examination has caused any significant
bias in the data analysis. Moreover, any inconsistency in
image reading causes inaccuracy and thus random noise
to the results leading in loss of power rather than in a
systematic error.
Second, our study subjects have been selected based
on their asbestos exposure, which itself appeared not to
be a significant predictor of emphysematous changes in
the logistic regression model (data not shown). More-
over, it is highly likely that the study subjects have been
occupationally exposed to other particles, such as dust,
which can contribute to the development of emphy-
sema. Unfortunately, dust exposure data was not avail-
able. However, our patient material was considerably
large and a lot of ex- and current smokers were
included in it. This is useful in demonstrating the
genetic predisposition to emphysema, which probably
would not have manifested to such degree without
smoking.
Third, the multiple comparisons performed increase
the possibility of detecting false positive associations.
We did not perform any correction for multiple testing
for a couple of reasons. First, most of the methods cor-
recting for multiple testing are very conservative, and it
is not clear, e.g., what is the number of comparisons you
should adjust for [27]. In addition, based on previous
findings, we had an a priori hypothesis for each poly-
morphism chosen, which reduces the need for correc-
tion. Yet, these results self-evidently should be
considered with caution until replicated in another
study population.
The fact that only four SERPINE2 SNPs were exam-
ined in the current study could also be considered as a
potential limitation. However, these SNPs were chosen
based on several previous association studies, and two of
them (rs729631 and rs975278) have been associated to
COPD and related phenotypes in four different reports
[6,7,11,12]. In addition, due to the limited number of
women in the study the findings should naturally be
generalized to females with caution.
Currently, functional consequences of none of the stu-
died SNPs are known. It is, however, possible that the
Table 3 Distribution of radiologic signs in relation to emphysema subtypes
Radiologic signs
Phenotype No changes#
N (%)
Any changes*
N (%)
Subnormal changes¶
N (%)
Pathological changes+
N (%)
Emphysema§ 599 (63.0) 352 (37.0) 231 (24.3) 121 (12.7)
Centrilobular 723 (76.0) 228 (24.0) 105 (11.0) 123 (12.9)
Paraceptal 781 (82.1) 170 (17.9) 94 (9.9) 76 (8.0)
Panlobular 783 (82.3) 168 (17.7) 109 (11.5) 59 (6.2)
Bullae 826 (86.9) 125 (13.1) 90 (9.5) 35 (3.7)
#Number of subjects with no emphysematous changes
*Number of subjects with emphysema score positive
¶Number of subjects with emphysema score less than one (less than two in emphysema sum score)
+Number of subjects with emphysema score one or higher (two or higher in emphysema sum score)
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Table 4 Distribution of SERPINE2 genotypes according to the existence and severity of panlobular emphysematous changes
Genotype No radiologic changes#
N (%)
Radiologic changes*
N (%)
OR (95% CI)¶ Subnormal changes+
N (%)
OR (95% CI)¶ Pathologcal changes++
N (%)
OR (95% CI)¶
rs729631
G/G 500 (64.6) 85 (51.2) 1.0 60 (56.1) 1.0 25 (42.4) 1.0
G/C 245 (31.7) 70 (42.2) 1.66 (1.15-2.38) 42 (39.3) 1.43 (0.93-2.20) 28 (47.4) 2.19 (1.23-3.91)
C/C 29 (3.7) 11 (6.6) 2.22 (1.05-4.72) 5 (4.7) 1.43 (0.52-3.92) 6 (10.2) 4.37 (1.61-11.86)
#Number of subjects with no emphysematous changes
*Number of subjects with emphysema score positive
¶Adjusted for age, sex, PYs, and years of asbestos exposure
+Number of subjects with emphysema score less than one (less than two in emphysema sum score)
++Number of subjects with emphysema score one or higher (two or higher in emphysema sum score)
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Table 5 Distribution of SERPINE2 haplotypes according to the existence and severity of panlobular emphysematous changes
Haplotype# No radiologic changes*
N (%)¶
Radiologic changes+
N (%)¶
OR (95% CI) ++ Subnormal changes±
N (%)¶
OR (95% CI) ++ Pathological changes§
N (%)¶
OR (95% CI) ++
GCψ 834 (53.3) 165 (49.1) 1.0 117 (53.7) 1.0 48 (40.7) 1.0
GT 429 (27.4) 79 (23.5) 0.92 (0.68-1.24) 49 (22.5) 0.80 (0.56-1.14) 30 (25.4) 1.20 (0.74-1.94)
CC 289 (18.5) 83 (24.7) 1.41 (1.04-1.92) 45 (20.6) 1.09 (0.75-1.59) 38 (32.2) 2.23 (1.41-3.54)
CT 14 (0.9) 9 (2.7) 3.72 (1.56-8.90) 7 (3.2) 3.98 (1.55-10.20) 2 (1.7) 2.71 (0.58-12.59)
#Composed of two SNPs: rs729631 and rs840088
ψWild type-wild type
*Number of subjects with no emphysematous changes
¶Data are presented as number of chromosomes (%)
+Number of subjects with emphysema score positive
++Adjusted for age, sex, PYs, and years of asbestos exposure
± Number of subjects with emphysema score less than one (two or higher in emphysema sum score)
§Number of subjects with emphysema score one (two or higher in emphysema sum score)
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intronic areas where these SNPs reside are important
regulatory elements for the transcription and translation
of the gene. Alternatively, the associations observed may
originate from LD with other yet unidentified suscept-
ibility genes in the 2q area.
Conclusions
In conclusion, our findings support the suggested asso-
ciation between SERPINE2 genotypes and development
of pulmonary emphysema. As a novel finding, our study
suggests that the SERPINE2 gene polymorphisms may
be involved particularly in the development of panlobu-
lar changes.
Additional material
Additional file 1: Table S1 - Association between SERPINE2
polymorphisms, emphysema findings and pulmonary function
separately in both case cohorts.
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